Filing Flows › Relay Therapeutics (RLAY) › Q1 2025
Relay Therapeutics (RLAY) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 5, 2025
Relay Therapeutics (RLAY) reported revenue of $7.7M for the first quarter 2025 (Q1 2025), -23% from a year earlier.
Relay Therapeutics, Q1 2025: revenue $7.7M (-23% year over year), net loss $77.1M, operating cash flow −$73.2M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $7.7M | — | -23% |
| Operating profit | −$84.9M | — | — |
| Net earnings | −$77.1M | — | — |
| Operating cash flow | −$73.2M | — | — |
What changed
Revenue was $7.7M in Q1 2025, down 23% year over year.
Operating costs exceeded revenue by $84.9M, an operating margin of -1105.2%. Total costs fell 8% while revenue fell 23%. The quarter ended with a net loss of $77.1M.
Operating cash flow was −$73.2M. Non-cash charges added back $1.2M of depreciation and $19.3M of share-based compensation. Working capital and other items used $16.7M. Capital expenditures of $384K exceeded it, leaving free cash flow of −$73.6M.
Questions
What was Relay Therapeutics' revenue in the first quarter 2025?
Relay Therapeutics (RLAY) reported revenue of $7.7M for the first quarter 2025 (Q1 2025), -23% from a year earlier.
Source: Relay Therapeutics 10-Q on SEC EDGAR.